<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCS</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="epub">2164-3202</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcs.2020.102003</article-id><article-id pub-id-type="publisher-id">WJCS-98247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Sclerotherapy for Varicose Veins of the Lower Limbs
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Papa</surname><given-names>Adama Dieng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Magaye</surname><given-names>Gaye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ndeye</surname><given-names>Fatou Sow</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Modibo</surname><given-names>Doumbia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Souleymane</surname><given-names>Diatta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Momar</surname><given-names>Sokhna Diop</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Papa</surname><given-names>Amath Diagne</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Gabriel Ciss</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Cardiovascular Center at Fann University Hospital, Dakar, Senegal</addr-line></aff><pub-date pub-type="epub"><day>12</day><month>02</month><year>2020</year></pub-date><volume>10</volume><issue>02</issue><fpage>19</fpage><lpage>23</lpage><history><date date-type="received"><day>11,</day>	<month>January</month>	<year>2020</year></date><date date-type="rev-recd"><day>10,</day>	<month>February</month>	<year>2020</year>	</date><date date-type="accepted"><day>13,</day>	<month>February</month>	<year>2020</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Summary:
   
  The diagnosis of venous insufficiency is increasing. Multiple techniques are available for its treatment. Chemical sclerotherapy has been performed for over 70 years. The technique improves lately. 
  <b>Objective:</b>
   This study was conducted to assess early results of foam sclerotherapy in Senegal
  . 
  <b>Patients and Methods: </b>
  This is a prospective and descriptive study conducted from January 1
  <sup>st</sup>
  , 2012 to December 31
  <sup>st</sup>
  , 2015 at cardiovascular center of Fann University hospital in Dakar, Senegal. Foam sclerotherapy was done in 76 patients. Polidocanol was used in concentration of 2%. Sclerotherapy was done several times in patients, every week, as much as needed to occlude varicose veins. We used venous compression in all patients
  . 
  <b>Results:</b>
   Foam sclerotherapy sessions permitted to get globally good results. In fact, tight feeling and painful leg disappear in 97% of patients. Decreases of edema were gotten in 97% of patients. For leg ulcer, 64% of complete healing was obtained. The main ulcer healing time was 47 days (18; 72).
   
  Some minor complications occurred. No major events, such as deep venous thrombosis or pulmonary embolism, were observed
  . 
  <b>Conclusion:</b>
   Foam sclerotherapy is an efficient technique for the treatment of varicose veins of the limbs. Also, it opens good perspectives for vein care.
 
</p></abstract><kwd-group><kwd>Sclerotherapy</kwd><kwd> Polidocanol</kwd><kwd> Varicose Vein</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Varicose veins diagnosis is improving in Africa [<xref ref-type="bibr" rid="scirp.98247-ref1">1</xref>]. Multiple treatments are possible. Among possible interventions, minimally invasive treatment such as foam sclerotherapy is now routinely used.</p><p>Chemical sclerotherapy has been performed for over 70 years [<xref ref-type="bibr" rid="scirp.98247-ref2">2</xref>]. Beside surgical care sclerotherapy is now an option in treatment of varicose veins of the lower limbs in our center.</p><p>The objective of this study was to assess indications and the early results of foam sclerotherapy for varicose veins in Senegal.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>This is a prospective and descriptive study conducted from January 1<sup>st</sup>, 2012 to December 31<sup>st</sup>, 2015 at cardiovascular center of Fann University hospital in Dakar, Senegal.</p><p>All patients with varicose veins who underwent sclerotherapy are included in the study.</p><p>The study was approved by the institutional review board, and informed consent was obtained from all participants.</p><p>Foam sclerotherapy was done in 76 patients.</p><p>Polidocanol was used in concentration of 2%. For mixture preparation, room air was used as the gas and rapid, manual displacement of the mixture between two syringes joined by a stopcock. These “home made” foams usually employ ratios of gas to liquid 1:3.</p><p>Sclerotherapy was done several times in patients, once a week, as much as needed to occlude varicose veins (<xref ref-type="table" rid="table1">Table 1</xref>), within one month. We used venous compression in all patients.</p><p>Patients in this study were diagnosed clinically for varicose veins of the lower limbs (vein dilatation, edema, ulcer), then with Doppler ultrasound for mapping.</p><p>Patients had tight leg, varicose veins, edema or ulcer, and superficial or deep reflux.</p><p>Patients with leg venous ulcer were 30%.</p><p>After closure of sessions, patients’ characteristics were collected in Excel form and statistical analyses were performed with the SPSS Statistics software.</p><p>Study evaluated epidemiologic results, clinical aspects, indications for sclerotherapy, and early results after foam sclerotherapy.</p></sec><sec id="s3"><title>3. Results</title><p>Multiple sclerotherapy sessions were done in patients.</p><p>The main follow up was 6 months (3; 24).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of sclerotherapy sessions in patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Number of sessions</th><th align="center" valign="middle" >Number of patients</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >13.15</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >31.57</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >35.52</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >13.15</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.57</td></tr></tbody></table></table-wrap><p>Foam sclerotherapy sessions permitted to get globally good results (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). In fact, tight feeling leg and painful leg disappears in 97% of patients. Decreases of edema were gotten in 97% of patients, as well varicose veins.</p><p>For leg ulcer, 64% of complete healing was obtained.</p><p>The main ulcer healing time was 47 days (18 - 72).</p><p>Some complications occurred. Superficial thrombophlebitis occurred in 5 patients (6.57%). Two patients experienced superficial limited skin necrosis.</p><p>After 6 months follow up, 3% of patients who experienced ulcer healing had a recurrence of disease.</p><p>No major events, such as deep venous thrombosis or pulmonary embolism, were observed.</p></sec><sec id="s4"><title>4. Discussion</title><p>Foam sclerotherapy is used to treat the varicose veins of the lower limbs. Expected results should be ranged in same rate than other minimally-invasive treatments to be recommended.</p><p>Good results require good planning, with respect of the order of the reflux points, working from larger caliber varicose veins to those with smaller caliber [<xref ref-type="bibr" rid="scirp.98247-ref3">3</xref>].</p><p>Polidocanol is used as sclerosant because it is well tolerated when delivered either as a liquid or foamed sclerosant [<xref ref-type="bibr" rid="scirp.98247-ref2">2</xref>].</p><p>Varicose vein closure may be achieved by direct venous injection of either a liquid or a foamed agent to get endothelial cell damage within affected vessels and thereby stimulate transmural vessel wall damage [<xref ref-type="bibr" rid="scirp.98247-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.98247-ref5">5</xref>].</p><p>Use of liquid is less efficient in term of vein occlusion [<xref ref-type="bibr" rid="scirp.98247-ref6">6</xref>], but symptoms like pain, signs of inflammation and pigmentation, and superficial thrombophlebitis appear more often with foam sclerosis [<xref ref-type="bibr" rid="scirp.98247-ref7">7</xref>].</p><p>Rasmussen [<xref ref-type="bibr" rid="scirp.98247-ref8">8</xref>] compared four techniques available for treatment of saphenous vein reflux (intravenous laser ablation, radiofrequency ablation, foam sclerotherapy, and conventional surgery) and observed that the recanalization rate after foam sclerotherapy was approximately 20%, without repercussion for symptoms.</p><p>Sclerotherapy is a low-cost, noninvasive treatment, easy accessible in developing countries.</p><p>Minor complications occurred with that technique. Also sclerotherapy can be repeated in case of recurrence of venous insufficiency.</p><p>This study had some limitations: the non-use of guiding catheter or guided- ultrasound procedure. But such techniques are more helpful for sclerotherapy of the Great Saphenous vein.</p><p>In perspective, ultrasound-guided sclerotherapy should be recommended for Great Saphenous Vein closure, to have better control, and good results [<xref ref-type="bibr" rid="scirp.98247-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.98247-ref10">10</xref>].</p></sec><sec id="s5"><title>5. Conclusion</title><p>Foam sclerotherapy is an efficient technique for the treatment of varicose veins of the limbs. Also, it opens good perspectives for vein care. Sclerotherapy is a low-cost, minimally-invasive and accurate procedure.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Dieng, P.A., Gaye, M., Sow, N.F., Doumbia, M., Diatta, S., Diop, M.S., Diagne, P.A. and Ciss, A.G. (2020) Sclerotherapy for Varicose Veins of the Lower Limbs. World Journal of Cardiovascular Surgery, 10, 19-23. https://doi.org/10.4236/wjcs.2020.102003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.98247-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dieng, P.A., Diatta, S., Ba, P.S., Touré, F.B., Ciss, A.G., Gaye, M., Fall, M.L., Diarra, O. and Ndiaye, M. (2014) Traitement chirurgical des varices des membres inférieurs a Dakar: étude rétrospective de 91 cas. Journal Africain de Chirurgie, 3, 23-27.</mixed-citation></ref><ref id="scirp.98247-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Eckmann, D.M. (2009) Polidocanol for Endovenous Microfoam Sclerosant Therapy. Expert Opinion Investigational Drugs, 18, 1919-1927.  
https://doi.org/10.1517/13543780903376163</mixed-citation></ref><ref id="scirp.98247-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Guex, J.J. (2005) Foam Sclerotherapy: An Overview of Use for Primary Venous Insufficiency. Seminars in Vascular Surgery, 18, 25-29.  
https://doi.org/10.1053/j.semvascsurg.2004.12.008</mixed-citation></ref><ref id="scirp.98247-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Eckmann, D.M., Kobayashi, S. and Li, M. (2005) Microvascular Embolization Following Polidocanol Microfoam Sclerosant Administration. Dermatologic Surgery, 31, 636-643. https://doi.org/10.1097/00042728-200506000-00004</mixed-citation></ref><ref id="scirp.98247-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Parsi, K., Exner, T., Connor, D.E., et al. (2008) The Lytic Effects of Detergent Sclerosants on Erythrocytes, Platelets, Endothelial Cells and Microparticles Are Attenuated by Albumin and Other Plasma Components in Vitro. European Journal of Vascular and Endovascular Surgery, 36, 216-223.  
https://doi.org/10.1016/j.ejvs.2008.03.001</mixed-citation></ref><ref id="scirp.98247-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rabe, E., Otto, J., Schliephake, D. and Pannier, F. (2008) Efficacy and Safety of Great Saphenous Vein Sclerotherapy Using Standardised Polidocanol Foam (ESAF): A Randomised Controlled Multicentre Clinical Trial. European Journal of Vascular and Endovascular Surgery, 35, 238-245. https://doi.org/10.1016/j.ejvs.2007.09.006</mixed-citation></ref><ref id="scirp.98247-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Davis, L.T. and Duffy, D.M. (1990) Determination of Incidence and Risk-Factors for Postsclerotherapy Telangiectatic Matting of the Lower-Extremity—A Retrospective Analysis. Journal of Dermatologic Surgery and Oncology, 16, 327-330.  
https://doi.org/10.1111/j.1524-4725.1990.tb00043.x</mixed-citation></ref><ref id="scirp.98247-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Rasmussen, L.H., Lawaetz, M., Bjoern, L., et al. (2011) Randomized Clinical Trial Comparing Endovenous Laser Ablation, Radiofrequency Ablation, Foam Sclerotherapy and Surgical Stripping for Great Saphenous Varicose Veins. British Journal of Surgery, 98, 1079-1087. https://doi.org/10.1002/bjs.7555</mixed-citation></ref><ref id="scirp.98247-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Myers, K.A., Jolly, D., Clough, A. and Kirwan, J. (2007) Outcome of Ultrasound-Guided Sclerotherapy for Varicose Veins: Medium-Term Results Assessed by Ultrasound Surveillance. European Journal of Vascular and Endovascular Surgery, 33, 116-121.  
https://doi.org/10.1016/j.ejvs.2006.09.005</mixed-citation></ref><ref id="scirp.98247-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hamel-Desnos, C., Ouvry, P., Benigni, J.P., Boitelle, G., Shadeck, M., Desnos, P., et al. (2007) Comparison of 1% and 3% Polidocanol Foam in Ultrasound Guided Sclerotherapy of the Great Saphenous Vein: A Randomised, Double-Blind Trial with 2 Year Follow-Up. European Journal of Vascular and Endovascular Surgery, 34, 723-729. https://doi.org/10.1016/j.ejvs.2007.07.014</mixed-citation></ref></ref-list></back></article>